Related Experiment Video
Updated: Apr 12, 2026
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Prognostic and predictive value of MET deregulation in non-small cell lung cancer
Giovanna Finocchiaro1, Luca Toschi1, Letizia Gianoncelli1
1Department of Medical Oncology, Department of Medical Oncology, Istituto Clinico Humanitas IRCCS, Rozzano, Milan, Italy.
Abstract:
Recent progress in cancer biology has led to the discovery of increasing number of oncogene alterations that have dramatically changed the paradigm of lung cancer treatment. MET is a tyrosine kinase receptor for the hepatocyte growth factor (HGF) that is deregulated in several malignancies, including non-small cell lung cancer (NSCLC). Abnormal MET-HGF signaling pathway activation can occur via different mechanisms, including HGF and/or MET overexpression, MET gene amplification, mutations or rearrangements. MET protein overexpression and increased MET gene number have been identified as poor prognostic factors in several series of surgically resected NSCLC making this receptor an attractive target for cancer treatment. Several clinical trials have recently evaluated the activity of a variety of anti-MET strategies in NSCLC patients with or without molecular selection with a variable degree of success, underscoring the need of establishing the best predictive biomarker for the identification of responding patients.
Insights
Targeting the MET-HGF pathway in non-small cell lung cancer (NSCLC) shows promise. Identifying the best predictive biomarker is crucial for patient selection in anti-MET therapies.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- The MET-HGF signaling pathway is frequently deregulated in non-small cell lung cancer (NSCLC).
- Mechanisms of MET-HGF pathway activation include overexpression, gene amplification, mutations, and rearrangements.
- MET alterations are associated with poor prognosis in NSCLC, making MET a key therapeutic target.
Purpose of the Study:
- To review the role of MET-HGF signaling in NSCLC pathogenesis.
- To summarize recent anti-MET therapeutic strategies evaluated in clinical trials for NSCLC.
- To highlight the need for predictive biomarkers to guide anti-MET therapy selection.
Main Methods:
- Review of recent scientific literature and clinical trial data on MET-targeted therapies in NSCLC.
- Analysis of the mechanisms driving MET dysregulation in lung cancer.
- Evaluation of the efficacy and limitations of current anti-MET strategies.
Main Results:
- MET pathway dysregulation is a common event in NSCLC, driven by various genetic and protein alterations.
- Clinical trials of anti-MET agents in NSCLC have shown variable success.
- The identification of predictive biomarkers is essential for optimizing patient response.
Conclusions:
- MET-targeted therapies represent a promising avenue for NSCLC treatment.
- Further research is needed to establish reliable predictive biomarkers for MET-targeted therapies.
- Personalized treatment strategies based on molecular profiling are critical for improving outcomes in NSCLC.
More Related Videos
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
08:14MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017